Use of sirolimus in kidney transplantation

Progress in Transplantation

Volumn 11, Issue 1, 2001, Pages 29-32

  Podbielski, J ^a   Schoenberg, L ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BROMOCRIPTINE; CARBAMAZEPINE; CIMETIDINE; CISAPRIDE; CLARITHROMYCIN; CLOTRIMAZOLE; CYCLOSPORIN; DANAZOL; DILTIAZEM; DRUG VEHICLE; ERYTHROMYCIN; FLUCONAZOLE; INDINAVIR; ITRACONAZOLE; KETOCONAZOLE; METOCLOPRAMIDE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NICARDIPINE; PHENOBARBITAL; PHENYTOIN; RAPAMYCIN; RIFABUTIN; RIFAMPICIN; RITONAVIR; STEROID; TACROLIMUS; TROLEANDOMYCIN; UNINDEXED DRUG; VALPROIC ACID; VERAPAMIL;

ARTICLE; CELL MATURATION; CELL PROLIFERATION; CLINICAL TRIAL; DISEASE SEVERITY; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG MONITORING; DRUG USE; DRUG WITHDRAWAL; GRAFT REJECTION; HUMAN; HYPERLIPIDEMIA; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; LEUKOPENIA; META ANALYSIS; NEPHROTOXICITY; STEROID THERAPY; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 0035078384     PISSN: 15269248     EISSN: None     Source Type: Journal    
DOI: 10.7182/prtr.11.1.5235m177144q114j     Document Type: Article

References (9)

1. Synergistic activity of the triple combination: Cyclosporine, rapamycin, and brequinar
2. The role of rapamycin in chronic rejection prophylaxis: A theoretical consideration
3. Rapamycin selectively inhibits interleukin-2 activation of P70 s6 kinase
4. Target of rapamycin in yeast, TOR2, is essential phosphatidylinositol kinase homolog required for G1 progression
5. Sirolimus, a new, potent immunosuppressive agent
6. The side effect profile of sirolimus: A phase I study in quiescent cyclosporine-prednisone treated renal transplant patients
7. The potential role of rapamycin in pediatric transplantation as observed from adult studies
8. Sirolimus (Rapamune) rapamycin is more effective than azathioprine to reduce the incidence of acute renal allograft rejection episodes when used in combination with cyclosporine and prednisone: A phase III U.S. multicenter trial